Welcome to our dedicated page for Annexon news (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon stock.
Annexon, Inc. (NASDAQ: ANNX) is a clinical-stage biopharmaceutical company advancing therapies targeting C1q to address neuroinflammatory and autoimmune disorders. This page provides investors and researchers with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements about Annexon’s pipeline candidates including ANX005 for Guillain-Barré syndrome, ANX007 for geographic atrophy, and ANX1502 for systemic autoimmune conditions. Our curated news collection delivers verified press releases and analysis to support informed decision-making.
Key updates include clinical trial progress, scientific presentations, partnership announcements, and regulatory filings. All content is vetted for accuracy and relevance to complement inhibition therapies.
Bookmark this page for streamlined access to Annexon’s latest developments in targeting upstream complement pathways. Check regularly for authoritative updates on novel treatments for diseases with high unmet medical needs.
Annexon (ANNX) is showcasing its leadership in Guillain-Barré Syndrome (GBS) research at the American Academy of Neurology Annual Meeting 2025. The company will present Phase 3 trial data for ANX005, their potential first targeted therapy for GBS, during an oral plenary session on April 8.
Key highlights include an educational symposium on GBS care and the classical complement pathway, featuring expert presenters from leading medical institutions. Additionally, Annexon is launching 'Move GBS Forward,' a disease education campaign at Booth #2133 to promote awareness of GBS's impact and encourage prompt diagnosis.
GBS affects approximately 150,000 people worldwide annually and currently has no FDA-approved therapies. ANX005, a first-in-kind monoclonal antibody, is designed to block C1q with a single infusion to stop neuroinflammation and nerve damage during acute GBS phases.
Annexon (ANNX) has granted stock options to a new non-executive employee as part of its 2022 Employment Inducement Award Plan. The equity award, approved on March 12, 2025, complies with Nasdaq Listing Rule 5635(c)(4).
The grant includes options to purchase 35,000 shares of Annexon common stock with a ten-year term and an exercise price of $2.60 per share, matching the closing price on March 14, 2025. The options vest over 4 years, with 25% vesting after the first year and the remaining 1/48th vesting monthly thereafter, contingent on continued employment.
Annexon (NASDAQ: ANNX) reported its Q4 and full-year 2024 financial results, highlighting progress across its late-stage clinical platform. The company maintains a strong financial position with $312 million in cash and investments as of December 31, 2024, providing runway into H2 2026.
Key developments include:
- ANX005 for Guillain-Barré Syndrome (GBS) advancing toward pre-BLA meeting in H1 2025
- Established global registration path for ANX007 as potential first vision-preserving treatment for dry AMD with GA
- Ongoing proof-of-concept trial for ANX1502, first-in-kind oral C1s inhibitor
Financial results show R&D expenses of $43.4M for Q4 2024 ($119.4M full-year), compared to $23.3M in Q4 2023 ($113.8M full-year). Net loss was $48.6M for Q4 2024 ($138.2M full-year), versus $27.9M in Q4 2023 ($134.2M full-year).
Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases, has announced its participation in the TD Cowen 45th Annual Health Care Conference.
The company's president and CEO, Douglas Love, will deliver a presentation on March 4, 2025, at 11:50 a.m. EST. Interested parties can access a live webcast of the presentation through the 'Events & Presentations' section on Annexon's Investors page. The presentation recording will remain available on the company's website for 30 days afterward.
Annexon (ANNX) has granted stock options to six new non-executive employees as part of its 2022 Employment Inducement Award Plan. The equity awards, approved on February 10, 2025, comply with Nasdaq Listing Rule 5635(c)(4). The employees received options to purchase a total of 542,000 shares of Annexon common stock at an exercise price of $3.07 per share, matching the closing price on February 14, 2025.
The options have a ten-year term and vest over four years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
Annexon (NASDAQ: ANNX) announced presentations highlighting their ANX007 treatment for geographic atrophy (GA) at the Macula Society 48th Annual Meeting. ANX007, a first-in-kind, non-pegylated antigen-binding fragment, is designed to block C1q locally in the eye through intravitreal formulation.
The treatment has demonstrated significant vision preservation in best corrected visual acuity (BCVA) and low luminance visual acuity (LLVA), along with preservation of central retinal photoreceptors. Two presentations are scheduled for February 13, 2025: Dr. Rahul Khurana will discuss the impact of C1q inhibition on visual acuity protection, while Dr. Eleonora Lad will present on C1q inhibition's role in attenuating microglia-induced neuronal injury.
Annexon (Nasdaq: ANNX) has outlined its 2025 outlook, emphasizing key milestones for its flagship programs. The company is advancing three major therapies:
ANX005 for Guillain-Barré Syndrome (GBS), the first targeted therapy in this area, showed promising results in a pivotal Phase 3 trial, improving muscle strength and functional recovery. A Biologics License Application (BLA) submission is planned for the first half of 2025.
ANX007 for Geographic Atrophy (GA) is the first neuroprotective therapy showing significant vision preservation in Phase 2 trials. Enrollment for the Phase 3 ARCHER II trial is expected to complete in the second half of 2025.
ANX1502, an oral C1s inhibitor, aims to treat autoimmune diseases. Clinical proof-of-concept data is expected in the first quarter of 2025. The company has a cash runway into the second half of 2026 to support these developments.
CEO Douglas Love highlighted the company's progress, noting that ANX005 could displace current GBS treatments, ANX007 could replicate significant vision protection, and ANX1502 could disrupt current autoimmune disease treatments.
Annexon, a biopharmaceutical company listed on Nasdaq under the ticker ANNX, has appointed William “BJ” Jones to its board of directors. Mr. Jones brings 30 years of experience in the biotechnology industry, focusing on U.S. and global commercial operations.
According to Douglas Love, Annexon's CEO, Mr. Jones's expertise will be important as the company advances its late-stage clinical therapies, specifically ANX005 for Guillain-Barré Syndrome and ANX007 for geographic atrophy, toward commercialization.
Mr. Jones currently serves as the Chief Commercial Officer at NewAmsterdam Pharma and has a history of successful product launches, including roles at Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, and NitroMed. He has been involved in the commercialization of major brands like Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil®, and Excedrin Migraine®.
Mr. Jones holds an M.B.A from Stanford Graduate School of Business and an M.S. in Industrial Engineering from Texas A&M University.
Annexon Biosciences (Nasdaq: ANNX), a biopharmaceutical company advancing late-stage clinical therapies for neuroinflammatory diseases, announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference.
Douglas Love, President and CEO, will present on Tuesday, January 14, 2025, at 3:00 p.m. PST. The presentation will be available via a live webcast under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay will be accessible on the website for 30 days post-event.
Annexon (NASDAQ: ANNX) has granted stock options to nine new non-executive employees under its 2022 Employment Inducement Award Plan. The equity awards, approved on December 10, 2024, comply with Nasdaq Listing Rule 5635(c)(4). The grants total 901,000 shares of Annexon common stock with an exercise price of $4.44 per share, based on the closing price on December 13, 2024. The options have a ten-year term and vest over 4 years, with 25% vesting after the first year and the remaining vesting monthly at 1/48th, contingent on continued employment.
FAQ
What is the current stock price of Annexon (ANNX)?
What is the market cap of Annexon (ANNX)?
